Entry Name Teneligliptin and canagliflozin;
Component (Teneligliptin hydrobromide hydrate [DR:
D09756 ] | Teneligliptin [DR:
D08616 ]), Canagliflozin [DR:
D09592 ]
Class Antidiabetic agentDG02044 Hypoglycemic agentDG03035 Combination of DPP-4 inhibitor and SGLT2 inhibitorDG01633 CYP3A/CYP3A4 substrateDG02913 CYP3A4 substrateDG02924 UGT substrateDG03188 UGT1A9 substrateDG03189 UGT2B4 substrateDG01665 ABCB1 substrateDG01622 ABCB1 inhibitorDG03306 FMO substrateDG03191 FMO1 substrateDG02950 FMO3 substrate Remark Therapeutic category: 3969
Efficacy Antidiabetic
Comment Teneligliptin is a substrate of CYP3A4, FMO1 and FMO3.
Metabolism Enzyme: CYP3A4 [HSA:
1576 ], FMO1 [HSA:
2326 ], FMO3 [HSA:
2328 ], UGT1A9 [HSA:
54600 ], UGT2B4 [HSA:
7363 ]
Transporter: ABCB1 [HSA:
5243 ]
Interaction Transporter inhibition: ABCB1 [HSA:
5243 ]
DDI search Brite Therapeutic category of drugs in Japan [BR:br08301 ]br08330 ]br08332 ]br08309.html ] BRITE hierarchy Other DBs LinkDB All DBs
